Aldeyra Therapeutics, Inc.

Equities

ALDX

US01438T1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.93 ^USD	-0.25%		+1.81%	+11.97%

Apr. 25	Transcript : Aldeyra Therapeutics, Inc. - Special Call
Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ

Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 07, 2024 at 04:07 pm EST

Aldeyra Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 37.54 million compared to USD 62.02 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to USD 1.06 a year ago.

Latest news about Aldeyra Therapeutics, Inc.

Transcript : Aldeyra Therapeutics, Inc. - Special Call	Apr. 25
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target	Apr. 03	MT
Transcript : Aldeyra Therapeutics, Inc. - Special Call	Mar. 28
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease	Mar. 28	CI
Aldeyra Therapeutics Insider Sold Shares Worth $580,760, According to a Recent SEC Filing	Mar. 13	MT
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of Rasp Platform in Systemic and Retinal Inflammatory Diseases	Jan. 04	CI
Aldeyra Therapeutics, Inc. and Abbvie to Enter into the Co-Development, Co-Commercialization and License Agreement	Dec. 21	CI
Aldeyra Therapeutics Shares Jump as Skin Drug Shows Significant Improvement in Clinical Trial	Dec. 19	MT
Transcript : Aldeyra Therapeutics, Inc. - Special Call	Dec. 19
Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study	Dec. 19	RE
Aldeyra Therapeutics' eczema drug succeeds in mid-stage study	Dec. 19	RE
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	Dec. 19	CI
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
Transcript : Aldeyra Therapeutics, Inc. - Special Call	Nov. 28
Aldeyra NDA for Reproxalap Did Not Demonstrate Efficacy for Dry Eye Treatment	Nov. 27	MT
Aldeyra Therapeutics Says Additional Trial Needed For FDA Approval of Dry-Eye Disease Treatment	Nov. 27	DJ
Aldeyra Therapeutics Halted After-Hours - FDA Says NDA Did Not Demonstrate 'Efficacy in Treating Ocular Symptoms Associated With Dry Eyes'; Additional Study Recommended	Nov. 27	MT
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease	Nov. 27	CI
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Health Care Up Amid Mixed Earnings -- Health Care Roundup	Nov. 01	DJ
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Nov. 01	MT
Sector Update: Health Care	Nov. 01	MT
Aldeyra Shares Continue to Rally After AbbVie Agrees to Licensing Option	Nov. 01	DJ

Chart Aldeyra Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.93 USD

Average target price

9.571 USD

Spread / Average Target

+143.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALDEYRA THERAPEUTICS, INC.	+11.97%	233M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs